Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The same but different

Alizyme plc thinks its ATL-962 lipase inhibitor to treat obesity may have better tolerability and similar efficacy to Xenical orlistat, a marketed lipase inhibitor from Roche, which has not been well accepted because

Read the full 339 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers